Latest moves
中文-
Chip stocks fall 9% as doubts over AI's payoff and Nvidia's turmoil deepen
Friday's drop is the latest leg of a slide that began in June. Nvidia's profit is still rising; what investors will pay for it has fallen.
- GAP Up 12.1% New
Gap jumps 12% even as it cuts its full-year outlook
Gap rose 12.1% after a quarterly profit beat, despite cutting its full-year outlook on a warm-weather slowdown. The shares had fallen 20.9% from Nov 4 to Nov 19.
-
The driver goes, the car stays: what robotaxis would reprice, from insurance to gas pumps
Waymo gives about half a million paid rides a week. If driverless taxis become common, money tied to drivers moves: wages, insurance, crash costs, fuel, parking.
-
Anthropic closes 17% above its IPO price after opening 34% higher in its Nasdaq debut
Anthropic's shares opened at $111.50 on Nasdaq, 34% above the $83 IPO price, and closed their first day at $97.17, up 17%.
-
Insurers slide as Medicare proposes recovering billions through Advantage plan audits
UnitedHealth closed down 19.8% and Humana 17.6% from Monday's close on Thursday, after CMS proposed broader Medicare Advantage audit recoveries back to 2018.
-
Summit Therapeutics: One Man, One Drug and a $500 Million Check
How a failed British antibiotics company became a $27.1 billion bet on a drug from China, controlled by one investor, and why the FDA said no.
-
Why gold and copper stocks fell harder than the metals
Gold and copper fell as rate-hike bets and a firm dollar weighed on metals and Reuters cited doubts about AI spending; mining stocks fell further.
- BRBR Up 24.1% New
BellRing jumps 24% as its 2027 profit outlook beats forecasts
The Premier Protein maker rose 24% after sales and its 2027 profit outlook beat forecasts, though margins fell sharply and it withdrew its long-term targets.
-
Big companies are raising billions, a sliver of stock at a time
Our 2026 screen found $84B raised through at-the-market share sales, led by Alphabet, Oracle and Strategy, with new shares reducing existing holders' ownership.
-
Nvidia Q3 2027: a $130 billion guide and a raised outlook in first report without Huang
Nvidia's $115.8 billion quarter beat its own guide by 7.3%; it guided to $130 billion and about 75% growth next year, as receivables and commitments grew again.
-
SAP up 60% since July as its cloud backlog defies the AI scare
SAP is up 60% from its July low as cloud backlog growth steadies and JPMorgan turns positive, with valuation accounting for most of the euro price swing.
- SLS Up 156.4% New
SELLAS nearly triples as its leukemia vaccine extends survival
SELLAS shares jumped after its Phase 3 REGAL trial of galinpepimut-S met its overall-survival goal in acute myeloid leukemia; it now plans to meet the FDA.
-
Moderna: what today's price assumes about its cancer platform
Our analysis of Moderna after its cancer-vaccine success and Analyst Day: what the price assumes about its platform, and what 50,000 simulations say about end-2030 value.
-
Netflix down 54% since June 2025 as investors pay less for its growth
Netflix has lost 54% since June 2025 while revenue per share rose 23%: investors pay far less for its sales. What the price implies, and what HBO's history shows.
- NU Up 11.7% New
Nu Holdings jumps 12% after a record profit and a better cost outlook
Nubank's owner rose 12% on Friday after a record $1.1 billion quarterly profit and a better cost-ratio forecast, regaining part of a 26% fall since mid-October.
-
Who would gain, and who would pay, in a SpaceX-Tesla merger?
Both boards have special committees studying a SpaceX-Tesla combination. Who decides, how a deal between two listed companies would be priced, and who gains or pays.
-
The $1 billion genome now costs about $100. Who got the money?
Reading a human genome once cost up to $1 billion; companies now quote about $100. What that changed in medicine and daily life, and who got the money.
-
The Rise and Reversals of Super Micro, an Unlikely Star of the AI Boom
From an $8 IPO in 2007 to the AI boom: how Super Micro twice soared on demand and twice fell on questions about its books and controls, told from the record.
-
PacBio's cash runway meets a moving breakeven date
PacBio can now sell up to $100 million of stock. What that adds to $199.4 million of cash, how fast cash has gone, and its record against its own targets.
- RUM Up 16.6% New
Rumble jumps 17% as its new AI cloud business tops 70% of sales
Rumble's owner rose about 17% after Q3 revenue nearly quadrupled to $96.6M, mostly from the AI cloud business it bought in June; it still had a net loss.